Format

Send to

Choose Destination
Best Pract Res Clin Endocrinol Metab. 2015 Dec;29(6):849-57. doi: 10.1016/j.beem.2015.10.001. Epub 2015 Oct 9.

Reprogramming of human exocrine pancreas cells to beta cells.

Author information

1
Diabetes Research Center, Vrije Universiteit Brussel, 1090 Brussels, Belgium; Department of Pediatrics, Division of Pediatric Endocrinology, Ghent University Hospital, and Department of Pediatrics and Genetics, Ghent University, Ghent, Belgium.
2
Diabetes Research Center, Vrije Universiteit Brussel, 1090 Brussels, Belgium.
3
Diabetes Research Center, Vrije Universiteit Brussel, 1090 Brussels, Belgium. Electronic address: Harry.Heimberg@vub.ac.be.

Abstract

One of the key promises of regenerative medicine is providing a cure for diabetes. Cell-based therapies are proving their safety and efficiency, but donor beta cell shortages and immunological issues remain major hurdles. Reprogramming of human pancreatic exocrine cells towards beta cells would offer a major advantage by providing an abundant and autologous source of beta cells. Over the past decade our understanding of transdifferentiation processes greatly increased allowing us to design reprogramming protocols that fairly aim for clinical trials.

KEYWORDS:

beta cell; diabetes; pancreas; reprogramming; transdifferentiation

PMID:
26696514
DOI:
10.1016/j.beem.2015.10.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center